DXC Technology to Participate in Upcoming Investor Conferences

ASHBURN, Va.--(BUSINESS WIRE)-- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services company, today announced it will participate in the following investor conferences:

J.P. Morgan’s Technology, Media, & Telecom 2024 Conference – Raul Fernandez, President and CEO, is hosting a series of investor meetings and a fire side chat at 3:10 pm EDT at The Westin Boston Seaport District, Boston on May 20, 2024. A webcast of the fire side chat will be available on the “Events and Presentations” section of DXC’s investor webpage at https://investors.dxc.com

TD Cowen’s Annual Technology, Media & Telecom 2024 Conference – Raul Fernandez, President and CEO, is hosting a series of investor meetings and a fire side chat at 2:25 pm EDT on May 29, 2024, at the InterContinental New York Barclay in New York, NY. A webcast of the fire side chat will be available on the “Events and Presentations” section of DXC’s investor webpage at https://investors.dxc.com

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com

Source: DXC Technology

Category: Investor Relations

View source version on businesswire.com: https://www.businesswire.com/news/home/20240503988543/en/

John Sweeney, CFA, Investor Relations, +1-980-315-3665, [email protected]

Sean B. Pasternak, Corporate Media Relations, +1-647-975-7326, [email protected]

Source: DXC Technology

You May Also Be Interested In

• Molson Coors Beverage Company Announces Regular Quarterly Dividend
• KBRA Assigns Preliminary Ratings to J.P. Morgan Mortgage Trust 2026-6 (JPMMT 2026-6)
• Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN